• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Grifols S.A.

    3/10/25 11:04:40 AM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRFS alert in real time by email
    6-K 1 tm258728d1_6k.htm FORM 6-K

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of March 2025

     

    Commission File No. 001-35193

     

    Grifols, S.A.

    (Translation of registrant’s name into English)

     

    Avinguda de la Generalitat, 152-158

    Parc de Negocis Can Sant Joan

    Sant Cugat del Valles 08174

    Barcelona, Spain

    (Address of registrant’s principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F x                                           Form 40-F ¨

     

     

     

     

     

     

    Grifols, S.A.

     

    TABLE OF CONTENTS

     

    Item   Sequential Page Number
         
    1. Other Relevant Information, dated March 10, 2025 3

     

    2

     

     

     

    Grifols, S.A.
     
    Avinguda de la Generalitat 152-158
    08174 Sant Cugat del Vallès
    Barcelona - SPAIN
     
    Tel. [34] 935 710 500
    Fax [34] 935 710 267
     
    www.grifols.com

     

    Pursuant to the provisions of Article 227 of Law 6/2023 of March 17, on Securities Markets and Investment Services, Grifols, S.A. (“Grifols” or the “Company”) hereby informs about the following

     

    OTHER RELEVANT INFORMATION

     

    Grifols wishes to address certain information published in a media outlet on 8 March 2025, specifically a front-page article titled “The CNMV reveals to the judge “continuous fraud” among the top executives of Grifols”, which also continues today. Neither the article nor its title reflect the reality.

     

    The article addresses certain statements made in the Legality Opinion from the CNMV’s legal service, which was used to support the decision of the CNMV’s Executive Committee on 25 September 2024 to initiate administrative sanctioning proceedings against Grifols, S.A. and its Directors. The proceedings concern allegations of including inaccurate data or omitting significant information in the consolidated annual financial reports and management report for 2021 to 2023 and the half-year financial information for 2023.

     

    The resolution mentioned above is primarily the act of initiating an administrative sanctioning procedure that can last up to one year and its purpose is to determine whether any potential infringements it addresses have occurred. Grifols, S.A. and the affected Directors, have the right to present their allegations and evidence—a right they have both exercised. However, the news article fails to mention the following important details:

     

    ·The Executive Committee which reflects the CNMV’s position, when adopting the initiation agreement, publicly communicated it to the market on the same date. In this communication, the CNMV explicitly stated that the alleged deficiencies which prompted the proceedings “did not result in material inaccuracies in the regulated accounting figures” and that “Grifols basic accounting figures were not incorrect (except for the accounting treatment of two specific transactions [....] which have been explained and separately restated by the company in the first half of 2024”.

     

    ·Both the Legality Opinion referenced in the news item and the resolution from the Executive Committee, when analysing the conduct of Grifols, S.A. and its Directors, clearly rule out any fraud (dolo) explicitly stating that: “As for the subjective title under which the infringement is attributed, it must be considered in both infringements as being of a culpable or negligent nature, since the facts do not reveal a predetermined and voluntary action aimed at achieving an illicit purpose nor contravening the rule”. Additionally, the Executive Committee highlights that the alleged irregularities did not result in any financial gain.

     

    3

     

     

     

     

     

    In Barcelona, 10 March 2025

     

     

       
    Nuria Martín Barnés  
    Secretary of the Board of Directors  

     

    4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

     

      Grifols, S.A.
         
         
      By: /s/ David I. Bell
        Name: David I. Bell
        Title: Authorized Signatory

     

    Date:  March 10, 2025

     

    5

     

    Get the next $GRFS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRFS

    DatePrice TargetRatingAnalyst
    2/12/2025Overweight
    Morgan Stanley
    3/12/2024Hold → Sell
    Deutsche Bank
    4/12/2023Equal-Weight → Overweight
    Morgan Stanley
    3/3/2023Overweight → Equal-Weight
    Morgan Stanley
    2/16/2023Underweight → Equal Weight
    Barclays
    1/18/2023Hold → Buy
    Jefferies
    4/8/2022Equal-Weight
    Morgan Stanley
    11/5/2021Buy → Hold
    Deutsche Bank
    More analyst ratings

    $GRFS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Grifols S.A.

      SC 13G/A - Grifols SA (0001438569) (Subject)

      11/14/24 11:46:03 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Grifols S.A. (Amendment)

      SC 13G/A - Grifols SA (0001438569) (Subject)

      2/9/24 2:45:34 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Grifols S.A.

      SC 13G - Grifols SA (0001438569) (Subject)

      2/9/24 2:21:17 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRFS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

      Believes Board Leadership Continuity and Continued Management Focus and Execution Will Drive Long-Term Shareholder Value Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the "Board") expressing Mason's support for the Company's recommended slate of director candidates for election at the Ordinary General Shareholders' Meeting to be held on June 4 and 5, 2025. The full text of the letter follows: May 28, 2025 Grifols, S.A. Avinguda de la Generalitat 152-158 0

      5/30/25 4:05:00 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease

      ‘Chronos-PD' is looking for biological signals that could indicate increased chance of developing Parkinson's disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real-world data on thousands of disease states in many therapeutic areasCutting-edge use of AI and proteomics technology paired with real-world evidence underscores the company's ongoing commitment to bold scientific innovation to benefit patients BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global

      1/14/25 6:00:00 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols

      Urges Improved Disclosure Around Key Issues for the Benefit of Grifols Shareholders Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Spanish National Securities Market Commission (the "CNMV") calling the CNMV's attention to the troubling and value destructive lack of transparency by Grifols and its Board of Directors (the "Board"). In the letter, Mason urges the CNMV to consider the benefits to all Grifols shareholders from improved disclosure around several key issues, including: Related-party transac

      1/13/25 10:00:00 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRFS
    Leadership Updates

    Live Leadership Updates

    See more
    • Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

      Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value Believes Rumored Brookfield Transaction Substantially Undervalues Grifols Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107873955/en/Historical Forward EV/EBITDA Multip

      11/8/24 3:54:00 PM ET
      $GRFS
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

      BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa

      4/18/23 10:30:00 AM ET
      $GRF
      $GRFS
      Finance/Investors Services
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

      Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is designated as Chairperson of Honor in recognition of his numerous contributionsSteven F. Mayer, former Co-Head of Global Private Equity and Chairman of the Investment Committee of private investment firm Cerberus Capital Management, L.P., with more than 10 years serving as a Grifols independent board member, is appointed as Executive ChairpersonChanges further evidence of the Board of Directors' focus on strategic objectives, operational excellence, and deleveraging balance sheetBARCELONA, Spain, Oct. 3, 2022 /PRNewswire/ -- Grifols (MCE: GRF)

      10/3/22 12:52:00 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRFS
    Financials

    Live finance-specific insights

    See more

    $GRFS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $GRFS
    SEC Filings

    See more
    • Grifols acquires its first plasma donation center in Canada

      BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced the acquisition of its first donation center in Canada as part of the company's commitment to increase the availability of lifesaving plasma medicines in the country. In a share-purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc's (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash. With the center, Grifols furthers

      1/4/22 12:30:00 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley resumed coverage on Grifols, S.A.

      Morgan Stanley resumed coverage of Grifols, S.A. with a rating of Overweight

      2/12/25 9:09:54 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grifols, S.A. downgraded by Deutsche Bank

      Deutsche Bank downgraded Grifols, S.A. from Hold to Sell

      3/12/24 1:36:28 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grifols, S.A. upgraded by Morgan Stanley

      Morgan Stanley upgraded Grifols, S.A. from Equal-Weight to Overweight

      4/12/23 8:07:28 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Grifols S.A.

      6-K - Grifols SA (0001438569) (Filer)

      6/5/25 3:58:16 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Grifols S.A.

      6-K - Grifols SA (0001438569) (Filer)

      5/12/25 12:36:55 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Grifols S.A.

      6-K - Grifols SA (0001438569) (Filer)

      5/6/25 12:01:34 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care